Protein Alternatives currently provides contract research services (CRO) in the fields of recombinant protein production, antibody development and preclinical validation, generating revenues that contribute to the financing of its internal R&D activities.

The company’s main value proposition is the development of innovative precision oncology products for colorectal cancer. These include: (i) a first-in-class multivalent antibody therapeutic designed to target the biological mechanisms driving metastasis and disease progression in metastatic colorectal cancer, and (ii) a genomic precision medicine test aimed at stratifying patients according to recurrence risk, supporting treatment decisions and optimizing the use of chemotherapy.

Together, these solutions seek to improve patient outcomes by enabling more effective and personalized treatment strategies while reducing the clinical and economic burden associated with colorectal cancer.

The current investment round (€8.2M Series A financing) is focused exclusively on the development of the company’s lead CDH17-LGR5 multivalent antibody therapeutic for metastatic colorectal cancer.